Oncopeptides AB (publ) (LON:0RN4)
London
· Delayed Price · Currency is GBP · Price in SEK 1.787
-0.081 (-4.34%)
At close: May 27, 2025
Oncopeptides AB Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 39.84 | 31.65 | 35.22 | 8.36 | 118.3 | - | Upgrade
|
| Revenue Growth (YoY) | 1.72% | -10.14% | 321.54% | -92.94% | - | - | Upgrade
|
| Cost of Revenue | 2.29 | 2.66 | -1.08 | 0.01 | 53.12 | - | Upgrade
|
| Gross Profit | 37.55 | 28.99 | 36.3 | 8.35 | 65.17 | - | Upgrade
|
| Selling, General & Admin | 196.92 | 197.28 | 188.48 | 142.2 | 873.81 | 654.19 | Upgrade
|
| Research & Development | 121.67 | 121.19 | 106.95 | 217.66 | 679.93 | 866.21 | Upgrade
|
| Other Operating Expenses | -4.28 | -6.9 | -6.34 | -4.57 | 3.9 | - | Upgrade
|
| Operating Expenses | 314.31 | 311.57 | 289.09 | 355.29 | 1,558 | 1,520 | Upgrade
|
| Operating Income | -276.76 | -282.59 | -252.79 | -346.94 | -1,492 | -1,520 | Upgrade
|
| Interest Expense | -11.36 | -12.66 | -5.79 | -0.88 | -0.95 | -1.49 | Upgrade
|
| Interest & Investment Income | 8.2 | 8.2 | 8.59 | 2.62 | 0.49 | 0.32 | Upgrade
|
| Currency Exchange Gain (Loss) | 2.84 | 2.84 | 1.54 | 8.96 | 71.54 | -70.87 | Upgrade
|
| Other Non Operating Income (Expenses) | 0 | 0 | - | - | 0 | - | Upgrade
|
| EBT Excluding Unusual Items | -277.08 | -284.21 | -248.45 | -336.24 | -1,421 | -1,592 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | -1.44 | - | - | Upgrade
|
| Pretax Income | -277.08 | -284.21 | -248.45 | -337.68 | -1,421 | -1,592 | Upgrade
|
| Income Tax Expense | 0.49 | 0.4 | 0.66 | 0.27 | 8.95 | 2.25 | Upgrade
|
| Net Income | -277.57 | -284.61 | -249.11 | -337.95 | -1,430 | -1,595 | Upgrade
|
| Net Income to Common | -277.57 | -284.61 | -249.11 | -337.95 | -1,430 | -1,595 | Upgrade
|
| Shares Outstanding (Basic) | 196 | 166 | 90 | 82 | 75 | 62 | Upgrade
|
| Shares Outstanding (Diluted) | 196 | 166 | 90 | 82 | 75 | 62 | Upgrade
|
| Shares Change (YoY) | 116.81% | 84.14% | 9.80% | 9.33% | 20.72% | 20.63% | Upgrade
|
| EPS (Basic) | -1.41 | -1.71 | -2.76 | -4.11 | -19.00 | -25.57 | Upgrade
|
| EPS (Diluted) | -1.41 | -1.71 | -2.76 | -4.11 | -19.00 | -25.57 | Upgrade
|
| Free Cash Flow | -261.88 | -260.93 | -279.61 | -423.02 | -1,517 | -1,314 | Upgrade
|
| Free Cash Flow Per Share | -1.33 | -1.57 | -3.09 | -5.14 | -20.14 | -21.06 | Upgrade
|
| Gross Margin | 94.25% | 91.59% | 103.06% | 99.93% | 55.09% | - | Upgrade
|
| Operating Margin | -694.63% | -892.91% | -717.74% | -4152.44% | -1261.64% | - | Upgrade
|
| Profit Margin | -696.66% | -899.29% | -707.30% | -4044.90% | -1209.11% | - | Upgrade
|
| Free Cash Flow Margin | -657.28% | -824.47% | -793.89% | -5063.03% | -1282.16% | - | Upgrade
|
| EBITDA | -274.28 | -280.12 | -250.35 | -344.93 | -1,491 | -1,519 | Upgrade
|
| D&A For EBITDA | 2.48 | 2.47 | 2.44 | 2.01 | 1.72 | 1.72 | Upgrade
|
| EBIT | -276.76 | -282.59 | -252.79 | -346.94 | -1,492 | -1,520 | Upgrade
|
Updated Feb 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.